Cardialysis
↗Rotterdam, Netherlands
Cardialysis is a specialized, independent Contract Research Organization (CRO) and Imaging Core Laboratory with an exclusive focus on cardiology. Founded in 1983 as a spin-off from the Thoraxcenter at Erasmus Medical Center in Rotterdam, the company provides full-service clinical trial support, including protocol design, project management, clinical monitoring, data management, and safety reporting for pharmaceutical, biotechnology, and medical device companies.
The company is recognized for its strong academic network, key-opinion-leader expertise, and extensive experience in managing multi-national clinical trials, registries, and investigator-initiated studies. Cardialysis operates globally with a focus on high-quality data and regulatory compliance, adhering to FDA, EMA, PMDA, and CFDA standards.
CLASSIFICATION
SIZE & FINANCIALS
Employees:51-200
Founded:1983
Ownership:private
Status:operating
PIPELINE
Modalities:Medical Devices, Pharmaceuticals, Biotechnology
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:European Cardiovascular Research Institute (ECRI) - Preferred partner for investigator-initiated trials, dabl - Partnership for ambulatory blood pressure monitoring services, AG Mednet - Preferred provider for image data submission
COMPETITION
Position:Niche Player
Competitors:IQVIA, Parexel, ICON plc, Medpace, Quanticate, Diagram B.V., SCIRENT
LINKS
Website:cardialysis.nl
⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Cardialysis and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Cardialysis. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.